Press Release
StemWave® Introduces Modus-F, A New FDA Listed Device With Cellular Response Therapy (CRT) Now Available For Orthopedic Use
March 28, 2022 – StemWave recently announced that their newest device Modus-F is now available for sale. StemWave recently received a Class l listing from the FDA and announced an exclusive North American partnership with Inceler Medikal, a leading global manufacturer.
StemWave’s newest product, Modus-F, uses uniquely designed Cellular Response Therapy (CRT) which utilizes an electrohydraulic system that generates focused acoustic waves that apply mechanical force and energy to living tissue.
StemWave will offer Modus-F to orthopedic healthcare providers like physical therapists, chiropractors, medical spas, and more.
Learn more about the StemWave® Device
About the Technology
90-Day ROI Guarantee
We are this confident in our offering: if you don't add profit to your bottom line within the first 90 days we will cover your payments.
Book a Free Demo